Zai Lab Announced That Data From Phase 1 Study Of ZL-1310 Will Be Presented During A Plenary Session At The EORTC-NCI-AACR Symposium, The Preliminary Results From The Ongoing Trial Will Address The Potential Of ZL-1310 For Small Cell Lung Cancer
Zai Lab Announced That Data From Phase 1 Study Of ZL-1310 Will Be Presented During A Plenary Session At The EORTC-NCI-AACR Symposium, The Preliminary Results From The Ongoing Trial Will Address The Potential Of ZL-1310 For Small Cell Lung Cancer
再鼎醫藥宣佈，ZL-1310的一期研究數據將在EORTC-新華保險-AACR研討會的全體會議上發佈，目前試驗的初步結果將探討ZL-1310用於小基站-5g肺癌的潛力
Zai Lab Announced That Data From Phase 1 Study Of ZL-1310 Will Be Presented During A Plenary Session At The EORTC-NCI-AACR Symposium, The Preliminary Results From The Ongoing Trial Will Address The Potential Of ZL-1310 For Small Cell Lung Cancer
再鼎醫藥宣佈，ZL-1310的一期研究數據將在EORTC-新華保險-AACR研討會的全體會議上發佈，目前試驗的初步結果將探討ZL-1310用於小基站-5g肺癌的潛力
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。